Patients with advanced BRCA-mutated breast cancer found no overall survival benefit with talazoparib
ABSTRACT: CTO71
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. Most patients included in the study went on to receive subsequent systemic therapies, which...
ABSTRACT: DDT01-03
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers...
Guillermina Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected as...
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy. Findings were published in the April 1online issue of the New England Journal of Medicine.
The multi-center, 20-site, Phase II ZUMA-2 study reported that 93% of patients...
Although metastatic castration-resistant prostate cancer (mCRPC) typically has limited response to immunotherapy, a subset of patients with...